Definiens, The Tissue Phenomics Company

📍 Munich, Germany🗓 Founded 1994👥 22 employees💰 Last funded Jun 2014
Biotechnology Research🌐 definiens.com
Website LinkedIn
We improve patient lives by unlocking the tissue phenome. In oncology, therapeutic strategies have shifted from a direct assault on cancer cells to recruiting the immune system for that purpose. Our mission is to accelerate breakthroughs for this approach by helping scientists leverage Tissue Phenomics to deepen understanding of disease biology and immune system mechanisms, to bring multi-omics data into a cancer-relevant context, and to facilitate the translation of new insights into novel therapies and treatment strategies. Our vision is to create unique patient profiles for an individualized standard of care, where patients experience fewer side effects and live longer. Definiens'​ Tissue Phenomics approach was awarded the 2013 Frost and Sullivan Company of the Year Award for Global Tissue Diagnostics and Pathology Imaging. For more information, please visit: www.definiens.com.
2
Total investors
0
Early stage
0
Mid stage
0
Late stage
1994
Founded

Investors

2 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
Germany
1
Frequently asked questions
Who invested in Definiens, The Tissue Phenomics Company?
Definiens, The Tissue Phenomics Company has 2 investors on record on gritt.io.
When did Definiens, The Tissue Phenomics Company last raise funding?
The most recent investment in Definiens, The Tissue Phenomics Company recorded on gritt.io was in June 2014.
When was Definiens, The Tissue Phenomics Company founded?
Definiens, The Tissue Phenomics Company was founded in 1994.
What industry is Definiens, The Tissue Phenomics Company in?
Definiens, The Tissue Phenomics Company operates in Biotechnology Research. Find similar Biotechnology Research investors on gritt.io.
Where is Definiens, The Tissue Phenomics Company based?
Definiens, The Tissue Phenomics Company is headquartered in Munich, Germany.